LAMIRA®, an eFlow® Technology nebulizer, expected to launch in Japan as a medical device for exclusive administration of ARIKAYCE® (amikacin liposome inhalation suspension)

LAMIRA®, an eFlow® Technology nebulizer, expected to launch in Japan as a medical device for exclusive administration of ARIKAYCE® (amikacin liposome inhalation suspension)

Published

PARI Pharma GmbH announces the authorization of the LAMIRA Nebulizer System for delivery of Insmed’s drug product ARIKAYCE®
(amikacin liposome inhalation suspension) in Japan.
 

Read the press release

Back to overview